CervoMed to Present at the Emerging Growth Conference
CervoMed (NASDAQ: CRVO) announced that Matthew Winton, Ph.D., Chief Commercial and Business Officer, will present a corporate presentation at the Emerging Growth Conference on Wednesday, October 22, 2025. The virtual presentation is scheduled for 11:25–11:55 AM ET. A live webcast and replay will be available via the provided webcast link and in the Investor section of the CervoMed website.
CervoMed (NASDAQ: CRVO) ha annunciato che Matthew Winton, Ph.D., Chief Commercial and Business Officer, terrà una presentazione aziendale alla Emerging Growth Conference mercoledì 22 ottobre 2025. La presentazione virtuale è prevista dalle 11:25 alle 11:55 (ET). Una diretta webcast e la replica saranno disponibili tramite il link fornito per lo webcast e nella sezione Investitori del sito CervoMed.
CervoMed (NASDAQ: CRVO) anunció que Matthew Winton, Ph.D., Chief Commercial and Business Officer, presentará una presentación corporativa en la Emerging Growth Conference el miércoles 22 de octubre de 2025. La presentación virtual está programada para las 11:25 a 11:55 a. m. hora del Este. Una transmisión en vivo y la repetición estarán disponibles a través del enlace de webcast proporcionado y en la sección de Inversores del sitio web de CervoMed.
CervoMed (NASDAQ: CRVO)는 Matthew Winton 박사, 최고 상업 및 비즈니스 책임자가 2025년 10월 22일 수요일에 열리는 Emerging Growth Conference에서 기업 프레젠테이션을 발표할 예정이라고 발표했습니다. 가상 프레젠테이션은 동부 표준시 11:25–11:55에 예정되어 있습니다. 실시간 생중계 및 재방송은 제공된 웹캐스트 링크와 CervoMed 웹사이트의 투자자 섹션에서 이용할 수 있습니다.
CervoMed (NASDAQ : CRVO) a annoncé que Matthew Winton, Ph.D., Chief Commercial and Business Officer, présentera une présente élaborée d'entreprise lors de la Emerging Growth Conference le mercredi 22 octobre 2025. La présentation virtuelle est prévue de 11:25 à 11:55 AM, heure de l'Est. Une webdiffusion en direct et une rediffusion seront disponibles via le lien de webcast fourni et dans la section Investisseurs du site Web de CervoMed.
CervoMed (NASDAQ: CRVO) gab bekannt, dass Matthew Winton, Ph.D., Chief Commercial and Business Officer, eine Unternehmenspräsentation auf der Emerging Growth Conference am Mittwoch, dem 22. Oktober 2025 halten wird. Die virtuelle Präsentation ist für 11:25–11:55 Uhr ET vorgesehen. Ein Live-Webcast und eine Wiederholung werden über den angegebenen Webcast-Link und im Investorenbereich der CervoMed-Website verfügbar sein.
CervoMed (NASDAQ: CRVO) أعلنت أن Matthew Winton، دكتوراه، الرئيس التجاري والشركات، سيقدّم عرضًا مؤسسيًا في مؤتمر النمو الناشئ الأربعاء 22 أكتوبر 2025. من المقرر أن يكون العرض الافتراضي في 11:25–11:55 صباحًا بتوقيت شرق الولايات المتحدة. سيكون البث المباشر والنسخة المعاد بثها متاحين عبر رابط البث المقدم وفي قسم المستثمرين من موقع CervoMed على الويب.
CervoMed (NASDAQ: CRVO)宣布，Matthew Winton 博士，首席商业与业务官，将在 2025年10月22日，星期三 于新兴增长大会上发表公司介绍。该线上演示定于 美国东部时间 11:25–11:55 进行。现场直播和回放将通过提供的网络直播链接以及 CervoMed 网站的投资者栏目提供。
- None.
- None.
BOSTON, Oct. 20, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today announced that Matthew Winton, Ph.D., Chief Commercial and Business Officer, will present at the Emerging Growth Conference, being held virtually on Wednesday, October 22, 2025.
Presentation Details
Format: Corporate Presentation
Date: Wednesday, October 22, 2025
Time: 11:25 – 11:55 AM ET
Webcast Link: https://goto.webcasts.com/starthere.jsp?ei=1717092&tp_key=1ddfafa563&sti=crvo
The webcast and replay of the presentation will be accessible in the Investor section of the CervoMed website https://www.cervomed.com/.
About CervoMed
CervoMed is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is currently developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in DLB and certain other major neurological disorders. The Company’s recently completed Phase 2b trial evaluated neflamapimod in patients with DLB.
Investor Contact:
PJ Kelleher
LifeSci Advisors
Investors@cervomed.com
617-430-7579
FAQ
When will CervoMed (CRVO) present at the Emerging Growth Conference?
Who is presenting for CervoMed (CRVO) at the October 22, 2025 conference?
How can investors watch the CervoMed (CRVO) Emerging Growth Conference presentation?
What is the duration of CervoMed's (CRVO) October 22, 2025 presentation?
Where will the CervoMed (CRVO) webcast replay be posted after the event?
